Evidence map›Paper›PMID 38363399›Full record

ArticleJournal of clinical immunology2024

Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency.

Adrian Baldrich, Dominic Althaus, Thomas Menter, Julia R Hirsiger, Julius Köppen, Robin Hupfer, Darius Juskevicius, Martina Konantz, Angela Bosch, Beatrice Drexler and 22 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 5 institutions in 6 countries.

Adrian Baldrich *Immunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Dominic Althaus *Gastroenterology and Hepatology, University Center for Gastrointestinal and Liver Diseases, Clarunis, Basel, Switzerland.
Thomas MenterPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Julia R HirsigerTranslational Immunology, Department of Biomedicine, University Hospital, Basel, Switzerland.
Julius KöppenImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Robin HupferImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Darius JuskeviciusMolecular Diagnostics, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Martina KonantzAllergy and Immunity Laboratory, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Angela BoschTranslational Diabetes, Department of Biomedicine, University Hospital, Basel, Switzerland.
Beatrice DrexlerDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Sabine GerullDepartment of Oncology and Hematology, Kantonsspital Aarau, Aarau, Switzerland.
Adhideb GhoshCompetence Center for Personalized Medicine, University of Zürich/Eidgenössische Technische Hochschule (ETH), Zurich, Switzerland.
Benedikt J MeyerImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Annaise JauchImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Katia PiniImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Fabio PolettiImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Caroline M BerkemeierDivision Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Ingmar HeijnenDivision Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Isabelle PanneGastroenterology and Hepatology, University Center for Gastrointestinal and Liver Diseases, Clarunis, Basel, Switzerland.
Claudia Cavelti-WederTranslational Diabetes, Department of Biomedicine, University Hospital, Basel, Switzerland.
Jan Hendrik NiessGastroenterology and Hepatology, University Center for Gastrointestinal and Liver Diseases, Clarunis, Basel, Switzerland.
Karen DixonCancer Immunology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Thomas DaikelerDepartment of Rheumatology, University Hospital Basel, Basel, Switzerland.
Karin HartmannAllergy and Immunity Laboratory, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Christoph HessImmunobiology Laboratory, Department of Biomedicine, University Basel Hospital, Basel, Switzerland.
Jörg HalterDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Jakob PasswegDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Alexander A NavariniDermatology, University Hospital Basel, Basel, Switzerland.
Hiroyuki YamamotoImmunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
Christoph T BergerTranslational Immunology, Department of Biomedicine, University Hospital, Basel, Switzerland.
Mike Recher *Immunodeficiency Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland. mike.recher@usb.ch.ORCID 0000-0002-9121-6936
Petr Hruz *Gastroenterology and Hepatology, University Center for Gastrointestinal and Liver Diseases, Clarunis, Basel, Switzerland. petr.hruz@usb.ch.ORCID 0000-0003-2767-0445
University Hospital of Basel · CHUniversity of Basel · CHUniversity of Zurich · CHKantonsspital Aarau · CHUniversity of Cambridge · GB

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_192652Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PP00P3_181038
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) occurring following allogeneic stem cell transplantation (aSCT) is a very rare condition. The underlying pathogenesis needs to be better defined. There is currently no systematic effort to exclude loss- or gain-of-function mutations in immune-related genes in stem cell donors. This is despite the fact that more than 100 inborn errors of immunity may cause or contribute to IBD. We have molecularly characterized a patient who developed fulminant inflammatory bowel disease following aSCT with stable 100% donor-derived hematopoiesis. A pathogenic c.A291G; p.I97M HAVCR2 mutation encoding the immune checkpoint protein TIM-3 was identified in the patient's blood-derived DNA, while being absent in DNA derived from the skin. TIM-3 expression was much decreased in the patient's serum, and in vitro-activated patient-derived T cells expressed reduced TIM-3 levels. In contrast, T cell-intrinsic CD25 expression and production of inflammatory cytokines were preserved. TIM-3 expression was barely detectable in the immune cells of the patient's intestinal mucosa, while being detected unambiguously in the inflamed and non-inflamed colon from unrelated individuals. In conclusion, we report the first case of acquired, "transplanted" insufficiency of the regulatory TIM-3 checkpoint linked to post-aSCT IBD.

Indexed as

Hepatitis A Virus Cellular Receptor 2Inflammatory Bowel DiseasesStem Cell TransplantationCytokinesHumansIntestinal MucosaCytokinesHepatitis A Virus Cellular Receptor 2HAVCR2immune checkpointInborn errors of immunityinflammatory bowel diseasestem cell transplantationTIM-3

Identifiers

PMID38363399
PMCPMC10873237
OpenAlexW4391883340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.